These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 94352)

  • 21. Characterization of the minor polypeptides in the foot-and-mouth disease particle.
    Sangar DV; Rowlands DJ; Cavanagh D; Brown F
    J Gen Virol; 1976 Apr; 31(1):35-46. PubMed ID: 177728
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antigenic analysis of poliovirus type 3 using monoclonal antibodies.
    Ferguson M; Minor PD; Magrath DI; Schild GC
    Dev Biol Stand; 1984; 57():151-5. PubMed ID: 6098495
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A comparative chemical and serological study of the full and empty particles of foot-and mouth disease virus.
    Rowlands DJ; Sangar DV; Brown F
    J Gen Virol; 1975 Mar; 26(3):227-38. PubMed ID: 235596
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antigenicity and immunogenicity of poliovirus capsid proteins.
    van Wezel AL; van der Marel P; Hazendonk TG; Boer-Bak V; Henneke MA
    Dev Biol Stand; 1983; 55():209-15. PubMed ID: 6203795
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serological prospects for peptide vaccines against foot-and-mouth disease virus.
    Parry NR; Ouldridge EJ; Barnett PV; Clarke BE; Francis MJ; Fox JD; Rowlands DJ; Brown F
    J Gen Virol; 1989 Nov; 70 ( Pt 11)():2919-30. PubMed ID: 2479714
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evidence for conformational changes of poliovirus precursor particles during virus morphogenesis.
    Wiegers KJ; Dernick R
    J Gen Virol; 1985 May; 66 ( Pt 5)():1037-44. PubMed ID: 2582079
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mimicry of viral epitopes with retro-inverso peptides of increased stability.
    Benkirane N; Guichard G; Briand JP; Muller S; Brown F; Van Regenmortel MH
    Dev Biol Stand; 1996; 87():283-91. PubMed ID: 8854029
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Capsid intermediates assembled in a foot-and-mouth disease virus genome RNA-programmed cell-free translation system and in infected cells.
    Grubman MJ; Morgan DO; Kendall J; Baxt B
    J Virol; 1985 Oct; 56(1):120-6. PubMed ID: 2411948
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Monoclonal antibodies to an Indian strain of type A foot-and-mouth disease virus.
    Tosh C; Venkataramanan R; Pattnaik B; Hemadri D; Sanyal A
    Acta Virol; 1999 Aug; 43(4):219-25. PubMed ID: 10749367
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neutralizing antibodies to all seven serotypes of foot-and-mouth disease virus elicited by synthetic peptides.
    Francis MJ; Hastings GZ; Clarke BE; Brown AL; Beddell CR; Rowlands DJ; Brown F
    Immunology; 1990 Feb; 69(2):171-6. PubMed ID: 2155177
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neutralizing epitopes of type O foot-and-mouth disease virus. II. Mapping three conformational sites with synthetic peptide reagents.
    Parry NR; Barnett PV; Ouldridge EJ; Rowlands DJ; Brown F
    J Gen Virol; 1989 Jun; 70 ( Pt 6)():1493-503. PubMed ID: 2471812
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antigenic specificity of porcine T cell response against foot-and-mouth disease virus structural proteins: identification of T helper epitopes in VP1.
    Rodríguez A; Sáiz JC; Novella IS; Andreu D; Sobrino F
    Virology; 1994 Nov; 205(1):24-33. PubMed ID: 7526534
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Amino acid changes outside the G-H loop of capsid protein VP1 of type O foot-and-mouth disease virus confer resistance to neutralization by antipeptide G-H serum.
    Krebs O; Ahl R; Straub OC; Marquardt O
    Vaccine; 1993; 11(3):359-62. PubMed ID: 7680514
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antigenicity and immunogenicity of synthetic peptides of foot-and-mouth disease virus.
    Meloen RH; Puyk WC; Meijer DJ; Lankhof H; Posthumus WP; Schaaper WM
    J Gen Virol; 1987 Feb; 68 ( Pt 2)():305-14. PubMed ID: 2434606
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cell-free translation of foot-and-mouth disease virus RNA into identifiable non-capsid and capsid proteins.
    Chatterjee NK; Polatnick J; Bachrach HL
    J Gen Virol; 1976 Sep; 32(3):383-94. PubMed ID: 61250
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neutralization of foot-and-mouth disease virus can be mediated through any of at least three separate antigenic sites.
    Xie QC; McCahon D; Crowther JR; Belsham GJ; McCullough KC
    J Gen Virol; 1987 Jun; 68 ( Pt 6)():1637-47. PubMed ID: 2438378
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Liposome encapsulated subunit (VP1) and virion vaccines against foot-and-mouth disease.
    Vasantha S; Antony A; Lal SM
    Acta Virol; 1987 Mar; 31(2):109-15. PubMed ID: 2886019
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antigenic characterization of poliovirus type 3 using monoclonal antibodies.
    Ferguson M; Minor PD; Magrath DI; Spitz M; Schild GC
    Rev Infect Dis; 1984; 6 Suppl 2():S510-3. PubMed ID: 6204368
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expression of the VP3-VP1 sequence of foot-and-mouth disease virus in Escherichia coli.
    Rossetti ML; Raupp RM; Farias SE; Ferreira LF; Zaha A
    Braz J Med Biol Res; 1993 Jun; 26(6):591-603. PubMed ID: 7504968
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunological priming with synthetic peptides of foot-and-mouth disease virus.
    Francis MJ; Fry CM; Rowlands DJ; Brown F; Bittle JL; Houghten RA; Lerner RA
    J Gen Virol; 1985 Nov; 66 ( Pt 11)():2347-54. PubMed ID: 2997370
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.